The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00630864
First received: February 27, 2008
Last updated: January 9, 2013
Last verified: January 2013
Results First Received: November 16, 2012  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Transthyretin-associated Amyloidosis With Polyneuropathy
Intervention: Drug: Fx-1006A

  Participant Flow


  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Tafamidis Participants with transthyretin (TTR) variants other than valine replaced by methionine at position 30 (V30M) received tafamidis (Fx-1006A) 20 milligram (mg) capsule orally once daily up to Week 6 in Part 1, participants who achieved TTR stabilization at Week 6 or as per investigator’s discretion continued to receive tafamidis (Fx-1006A) 20 mg capsule orally once daily up to Month 12 in Part 2.

Baseline Measures
    Tafamidis  
Number of Participants  
[units: participants]
  21  
Age  
[units: years]
Mean ± Standard Deviation
  63.10  ± 9.86  
Gender  
[units: participants]
 
Female     8  
Male     13  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Week 6   [ Time Frame: Week 6 ]

2.  Secondary:   Percentage of Participants With Stabilized Transthyretin (TTR) Tetramer at Month 6 and 12   [ Time Frame: Month 6, Month 12 ]

3.  Other Pre-specified:   Number of Participants With Treatment-Emergent Adverse Events (AEs)   [ Time Frame: Baseline up to 30 days after the last dose ]

4.  Other Pre-specified:   Number of Participants With Greater Than or Equal to Grade 3 Treatment-Emergent Adverse Events   [ Time Frame: Baseline up to 30 days after the last dose ]

5.  Other Pre-specified:   Number of Participants With Clinically Significant Treatment-Emergent Echocardiography (ECHO) Findings   [ Time Frame: Day 1 up to Month 12 ]

6.  Other Pre-specified:   Number of Participants With Clinically Significant Treatment-Emergent Electrocardiogram (ECG) Findings   [ Time Frame: Day 1 up to Month 12 ]

7.  Other Pre-specified:   Number of Participants With Clinically Significant Treatment-Emergent Holter Monitoring Findings   [ Time Frame: Day 1 up to Month 12 ]

8.  Other Pre-specified:   Number of Participants Who Discontinued Due to Clinical or Laboratory Adverse Events   [ Time Frame: Baseline up to Month 12 ]

9.  Other Pre-specified:   Change From Baseline in the Neuropathy Impairment Score (NIS) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

10.  Other Pre-specified:   Change From Baseline in the Neuropathy Impairment Score-Lower Limb (NIS-LL) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

11.  Other Pre-specified:   Percentage of Participants With Response to Treatment as Measured by Neuropathy Impairment Score - Lower Limb (NIS-LL) at Month 6, Month 12   [ Time Frame: Month 6, Month 12 ]

12.  Other Pre-specified:   Change From Baseline in Total Quality of Life (TQOL) Score at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

13.  Other Pre-specified:   Change From Baseline in Norfolk Quality of Life – Diabetic Neuropathy (QOL-DN) Domain Scores at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

14.  Other Pre-specified:   Change From Baseline in Nerve Conduction Studies (NCS) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

15.  Other Pre-specified:   Change From Baseline in Heart Rate Response to Deep Breathing (HRDB) at Month 6 and Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

16.  Other Pre-specified:   Change From Baseline in Modified Body Mass Index (mBMI) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

17.  Other Pre-specified:   Change From Baseline in Overall Quality of Life and Individual Domains of the Short-form-36 (SF-36) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

18.  Other Pre-specified:   Change From Baseline in Echocardiography (ECHO) Parameters at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

19.  Other Pre-specified:   Change From Baseline in Left Atrial Volume at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

20.  Other Pre-specified:   Change From Baseline in Left Ventricular (LV) End Systolic Volume, Left Ventricle (LV) Stroke Volume at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

21.  Other Pre-specified:   Change From Baseline in Fractional Shortening at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

22.  Other Pre-specified:   Change From Baseline in Left Ventricular (LV) Ejection Fraction at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

23.  Other Pre-specified:   Change From Baseline in Left Ventricular Mass (LVM) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

24.  Other Pre-specified:   Change From Baseline in Isovolumetric Relaxation Time (IVRT), Mitral Deceleration Time at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

25.  Other Pre-specified:   Change From Baseline in Aortic Annulus Diameter at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

26.  Other Pre-specified:   Change From Baseline in Tricuspid Peak Velocity at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

27.  Other Pre-specified:   Change From Baseline in Tricuspid Pulmonary Artery Systolic Pressure (PASP) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

28.  Other Pre-specified:   Change From Baseline in Doppler Data at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

29.  Other Pre-specified:   Change From Baseline in e:e’ Lateral Ratio , Ratio of Peak Mitral Early Diastolic and Atrial Contraction Velocity (E/A Ratio) at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

30.  Other Pre-specified:   Change From Baseline in Left Ventricular (LV) Mass/Voltage Ratio at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

31.  Other Pre-specified:   Change From Baseline in Left Atrial (LA) Volume Index at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

32.  Other Pre-specified:   Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) at Week 2, Week 6, Month 3, Month 6, Month 12   [ Time Frame: Baseline, Week 2, Week 6, Month 3, Month 6, Month 12 ]

33.  Other Pre-specified:   Change From Baseline in Karnofsky Performance Status Scale at Month 6, Month 12   [ Time Frame: Baseline, Month 6, Month 12 ]

34.  Other Pre-specified:   Change From Baseline in Troponin I Levels at Week 2, Week 6 , Month 3, Month 6, Month 12   [ Time Frame: Baseline, Week 2, Week 6 , Month 3, Month 6, Month 12 ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Pfizer ClinicalTrials.gov Call Center
Organization: Pfizer, Inc.
phone: 1-800-718-1021
e-mail: ClinicalTrials.gov_Inquiries@pfizer.com


No publications provided by Pfizer

Publications automatically indexed to this study:

Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT00630864     History of Changes
Other Study ID Numbers: FX1A-201, B3461022
Study First Received: February 27, 2008
Results First Received: November 16, 2012
Last Updated: January 9, 2013
Health Authority: United States: Food and Drug Administration